Nodom Combi (Dorzolamide, Timolol)

Dorzolamide/Timolol, the active ingredients in Nodom Combi, are a carbonic anhydrase inhibitor and a beta‑adrenergic blocker presented as eye drops for ocular use. The combination lowers intra‑ocular pressure and is indicated for patients with open‑angle glaucoma or ocular hypertension. It is administered topically as a sterile ophthalmic solution and is prescribed by eye care professionals.

GNH USA supplies Nodom Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and adheres to EU regulatory standards globally.

Nodom Combi, a combination antiglaucoma eye drop, acts on aqueous humor dynamics to lower intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic nerve damage. - Ocular hypertension: lowers eye pressure to decrease the risk of developing glaucoma. - Glaucoma (any type) as adjunct therapy: provides additional pressure reduction when monotherapy is insufficient.

The most frequently reported ocular and systemic reactions to Nodom Combi are listed below.

Common Side Effects: - Eye irritation or burning sensation. - Stinging or transient discomfort after instillation. - Blurred vision. - Dry eye or foreign body sensation. - Altered taste or bitter after drainage. - Headache.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Marked bradycardia or heart block. - Bronchospasm or worsening asthma. - Significant hypotension. - Persistent eye pain or vision loss. - Corneal edema.

Before prescribing Nodom Combi, clinicians should consider the following precautions. - Cardiac assessment: avoid in patients with severe bradycardia, heart block, or uncontrolled heart failure. - Respiratory evaluation: use with caution in asthma or chronic obstructive pulmonary disease. - Systemic beta‑blocker use: monitor for additive bradycardic or hypotensive effects. - Pregnancy and lactation: prescribe only if the potential benefit outweighs the risk. - Concomitant carbonic anhydrase inhibitors: assess for excessive intra‑ocular pressure reduction. - Store at room temperature: keep in the original container, protect from light and moisture.

Nodom Combi may interact with other systemic or ocular medications as follows.

Major Interactions (Avoid): - Non‑selective oral beta‑blockers (e.g., propranolol): risk of severe bradycardia and hypotension. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive reduction of aqueous humor production. - Other topical beta‑blocker eye drops: excessive ocular beta‑blockade.

Moderate Interactions (Monitor Closely): - Topical sympathomimetic agents (e.g., phenylephrine): may diminish the intra‑ocular pressure‑lowering effect. - Prostaglandin analogues (e.g., latanoprost): monitor intra‑ocular pressure for adequate control. - Systemic antihypertensives (e.g., ACE inhibitors): observe blood pressure for additive lowering. - Anticholinergic eye drops: assess for potential ocular surface irritation.